First Tracks Biotherapeutics, Inc. SEC filings TRAX
First Tracks Biotherapeutics, Inc. has 98 filings in SEC EDGAR's recent list, going back to Feb 6, 2026. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B3 | Prospectus | Nov 4, 2026 | — |
| 424B3 | Prospectus | Nov 4, 2026 | — |
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2026 | Nov 3, 2026 |
| EFFECT | Filing | Oct 29, 2026 | — |
| S-1 | Registration statement | Oct 26, 2026 | — |
| 8-K |
Current report
Material agreement
|
Oct 20, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Oct 15, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 13, 2026 | Oct 12, 2026 |
| 424B3 | Prospectus | Aug 13, 2026 | — |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Material agreement
|
Jun 22, 2026 | Jun 15, 2026 |
| 424B3 | Prospectus | May 15, 2026 | — |
| 424B3 | Prospectus | May 14, 2026 | — |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 14, 2026 | May 14, 2026 |
| EFFECT | Filing | May 12, 2026 | — |
| CORRESP | Letter to the SEC | May 8, 2026 | — |
| S-1 | Registration statement | May 8, 2026 | — |
| UPLOAD | Letter from the SEC | May 6, 2026 | — |
| DRS | Filing | May 1, 2026 | — |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Change to shareholder rights, Change in control, Officer or director change, Bylaw or fiscal year change, Other events
|
Apr 20, 2026 | Apr 20, 2026 |
| S-8 | Employee stock plan registration | Apr 17, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 3, 2026 | Apr 1, 2026 |
| SEC STAFF ACTION | Filing | Apr 1, 2026 | — |
| CERT | Filing | Apr 1, 2026 | — |
| 10-12B/A | Filing | Mar 27, 2026 | — |
| 10-12B | Filing | Mar 3, 2026 | — |
| DRS | Filing | Feb 6, 2026 | — |
Showing 30 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TRAX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 2091349
- Former names
- Biopharma Company, Inc. (until Feb 6, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.